Literature DB >> 7685367

Production of conformation-specific monoclonal antibodies against alpha 2 macroglobulin and their use for quantitation of total and transformed alpha 2 macroglobulin in human blood.

G Birkenmeier1, T Stigbrand.   

Abstract

Monoclonal antibodies against the human proteinase inhibitor, alpha 2 macroglobulin, have been produced by immunizing BALB/c mice with alpha 2 macroglobulin reacted with methylamine. Two antibodies have been characterized in detail with respect to their binding to native alpha 2 macroglobulin and to different derivatives of the inhibitor. The antibody alpha-1 was found to recognize only those forms of the inhibitor which were transformed by reaction with different proteinases or with methylamine. Binding of alpha-1 was mapped to a specific epitope localized within a distance of 138 amino acid residues from the C terminal end of alpha 2 macroglobulin. The C terminal end is assumed to be exposed during the transformation of the inhibitor and harbours the receptor recognition site. The monoclonal antibody alpha-11 was found to bind to all forms of the inhibitor indicating that its epitope is located in a region not involved in major conformational changes of the inhibitor. On the basis of the different reactivity patterns of alpha-1 and alpha-11 two enzyme-linked immunosorption assays were established for quantitation of total and transformed alpha 2 macroglobulin in human blood. The concentration of the two forms have been determined in a population of 114 healthy individuals giving values of 254 +/- 6.6 mg/dl (mean +/- SEM) of total alpha 2 macroglobulin and 1.07 +/- 0.05 mg/dl (mean +/- SEM) of the transformed inhibitor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685367     DOI: 10.1016/0022-1759(93)90407-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis.

Authors:  G Birkenmeier; R Frank
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

2.  Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor.

Authors:  G C Howard; U K Misra; D L DeCamp; S V Pizzo
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

3.  The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat.

Authors:  Susanne Kurz; René Thieme; Ronny Amberg; Marco Groth; Heinz-Georg Jahnke; Philipp Pieroh; Lars-Christian Horn; Marlen Kolb; Klaus Huse; Matthias Platzer; Daniela Volke; Faramarz Dehghani; Anton Buzdin; Kathrin Engel; Andrea Robitzki; Ralf Hoffmann; Ines Gockel; Gerd Birkenmeier
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

4.  Verification and characterization of an alternative low density lipoprotein receptor-related protein 1 splice variant.

Authors:  Marlen Kolb; Susanne Kurz; Angelika Schäfer; Klaus Huse; Andreas Dietz; Gunnar Wichmann; Gerd Birkenmeier
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.